- E-mailOivind.Torkildsen@uib.no
- Visitor AddressNevrologisk avdeling, Haukeland Universitetssykehus
- Postal AddressPostboks 78045020 Bergen
Academic article
- (2024). Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders.
- (2024). Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry.
- (2023). Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease. Journal of Clinical Endocrinology and Metabolism (JCEM). 1-7.
- (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. Multiple Sclerosis and Related Disorders. 7 pages.
- (2023). Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro. International Immunopharmacology. 1-5.
- (2023). Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. Journal of Neurology. 8 pages.
- (2023). Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. Multiple Sclerosis and Related Disorders. 8 pages.
- (2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurology. 702-713.
- (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. European Radiology. 3576-3587.
- (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and neuroinflammation. 1-10.
- (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry. 849-857.
- (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
- (2022). Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes. Multiple Sclerosis and Related Disorders.
- (2022). Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry. Journal of Mass Spectrometry and Advances in the Clinical Lab. 53-60.
- (2022). Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. Journal of Neurology, Neurosurgery and Psychiatry. 1-5.
- (2022). Hva vi kan lære av historien om lobotomi. Tidsskrift for Den norske legeforening. 7 pages.
- (2022). Cancer related mortality in multiple sclerosis. A population based cohort study . Multiple Sclerosis and Related Disorders. 1-6.
- (2022). Brief international cognitive assessment for MS (BICAMS) and global brain volumes in early stages of MS – A longitudinal correlation study. Multiple Sclerosis and Related Disorders.
- (2022). Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 645-650.
- (2022). Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology. 5901-5909.
- (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-10.
- (2021). Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study. Neurology. e2789-e2800.
- (2021). Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Multiple Sclerosis and Related Disorders. 1-7.
- (2021). Living with secondary progressive multiple sclerosis in Europe: Perspectives of multiple stakeholders. Neurodegenerative Disease Management. 9-19.
- (2021). Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study. Multiple Sclerosis and Related Disorders. 1-7.
- (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
- (2021). En ung kvinne med langvarig kvalme, oppkast og hikke. Tidsskrift for Den norske legeforening.
- (2021). Association of body mass index in Adolescence and young Adulthood and long-term risk of multiple Sclerosis: A Population-Based Study. Neurology. E2253-E2261.
- (2020). Serum NFL levels should be used to monitor multiple sclerosis evolution - No. Multiple Sclerosis.
- (2020). Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology. 7 pages.
- (2020). An immunocompromised woman in her twenties with abdominal pain and vaginal discharge. Tidsskrift for Den norske legeforening.
- (2020). A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. Multiple Sclerosis and Related Disorders. 1-7.
- (2019). The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). Multiple Sclerosis and Related Disorders. 1-6.
- (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Multiple Sclerosis. 1-9.
- (2019). Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Multiple Sclerosis. 1569-1580.
- (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology.
- (2018). α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis. 987-993.
- (2018). Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology. 73-77.
- (2018). International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis. 1-10.
- (2018). Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. Journal of Neuroimmunology. 61-65.
- (2017). Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and neuroinflammation. 1-8.
- (2017). Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. Multiple Sclerosis. 213-219.
- (2017). In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis. Journal of Proteome Research. 179-194.
- (2017). Glitazone use associated with reduced risk of Parkinson's disease. Movement Disorders. 1594-1599.
- (2017). Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Multiple Sclerosis. 395-402.
- (2017). An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 1627-1635.
- (2017). 1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International. 262-277.
- (2016). WT1 and interferon-β–vitamin D association in MS: a longitudinal study. Acta Neurologica Scandinavica. 309-312.
- (2016). Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 1064-1070.
- (2016). The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics & Bioinformatics.
- (2016). No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and neuroinflammation. 5 pages.
- (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
- (2016). Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskrift for Den norske legeforening. 1726-1729.
- (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
- (2016). Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis. BMJ Case Reports.
- (2015). Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology. 2713-2721.
- (2015). Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology. 21-28.
- (2015). Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
- (2015). Miljøets betydning ved multippel sklerose. Tidsskrift for Den norske legeforening. 856-860.
- (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
- (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
- (2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicantre study. Multiple Sclerosis. 1013-1024.
- (2015). Cerebrospinal fluid proteomics in multiple sclerosis. Biochimica et Biophysica Acta - Proteins and Proteomics. 746-756.
- (2015). Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology. 92-97.
- (2014). Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 141-144.
- (2014). Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology. 60-65.
- (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
- (2014). Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis. 1833-1840.
- (2013). Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway. Journal of Neurology. 1481-1488.
- (2013). Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis. Multiple Sclerosis. 451-457.
- (2013). Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nature Medicine. 595-602.
- (2013). No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Annals of Neurology. 430-432.
- (2013). Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Multiple Sclerosis. 1028-1034.
- (2013). Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity. PLOS ONE. 9 pages.
- (2013). Fat-soluble vitamins as disease modulators in multiple sclerosis. Acta Neurologica Scandinavica. 16-23.
- (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
- (2013). Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction. PLOS ONE. 5 pages.
- (2012). ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomised, double blind, placebo-controlled trial. Archives of Neurology. 1044-1051.
- (2012). Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurologica Scandinavica. 63-69.
- (2012). Vitamin D and disease activity in multiple sclerosis before and during interferon beta treatment. Neurology. 267-273.
- (2012). The cuprizone model: regional heterogeneity of pathology. APMIS - Journal of Pathologiy, Microbiology and Immunology. 648-657.
- (2012). Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurologica Scandinavica. 58-62.
- (2012). Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls. Acta Neurologica Scandinavica, Supplementum. 84-89.
- (2012). A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
- (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 pages.
- (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
- (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Experimental Neurology. 160-166.
- (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clinical Nutrition. 83-87.
- (2008). Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Archives of Neurology. 809-811.
- (2008). The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
- (2007). Immunomodulatory treatment of multiple sclerosis in Norway. Acta Neurologica Scandinavica. 46-50.
- (2006). Fc gamma R and multiple sclerosis: an overview. Acta Neurologica Scandinavica. 61-63.
- (2005). Lars Hertervig og Carl Fredrik Hill - kreativitet og psykisk sykdom. Tidsskrift for Den norske legeforening. 3450-3453.
- (2005). High dose methylprednisolone induces FcgammaR1 on granulocytes in MS-patients. Journal of Neuroimmunology. 138-142.
- (2005). Ethnic variations of IL-10 polymorphisms in a Sami and Norwegian population. Scandinavian Journal of Immunology. 71-74.
- (2005). Ethnic variation of Fc gamma receptor polymorphism in Sami and Norwegian populations. Immunology. 416-421.
Academic lecture
- (2022). Rituximab in the treatment of multiple sclerosis: A pharmacokinetic-pharmacodynamic model.
- (2015). Vitamin D og interferon-behandling ved multippel sklerose.
Editorial
- (2023). Editorial: New cerebrospinal fluid research to uncover mechanisms driving neurological and psychiatric diseases, volume II. Frontiers in Neurology.
- (2016). Can Vitamin D reduce inflammation in relapsing-remitting multiple sclerosis? Expert Review of Neurotherapeutics. 233-235.
Reader opinion piece
- (2010). Vitamin D-Dependent Rickets, HIA-DRB1, and the Risk of Multiple Sclerosis. Archives of Neurology. 1034-1035.
Short communication
- (2020). Tenofovir as a treatment option for multiple sclerosis. Multiple Sclerosis and Related Disorders.
- (2016). Trombolytisk behandling og trombektomi ved ukjent slagdebut. Tidsskrift for Den norske legeforening. 1363-1363.
- (2016). Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. Headache. 1035-1039.
- (2014). Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. Neurology: Neuroimmunology and neuroinflammation.
- (2008). Epstein-Barr virus reactivation and multiple sclerosis. European Journal of Neurology. 106-108.
Feature article
- (2022). Amming og behandling av multippel sklerose. Tidsskrift for Den norske legeforening. 1-5.
- (2018). Mann i 20-årene med svimmelhet, dobbeltsyn og perifer facialisparese. Tidsskrift for Den norske legeforening. 7 pages.
Letter to the editor
- (2024). Antiviral therapy with tenofovir in MS. Multiple Sclerosis and Related Disorders.
- (2023). Interferon β1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders.
- (2022). Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. Multiple Sclerosis and Related Disorders.
- (2018). Response to 'Seasonal variation of vitamin D and Epstein?Barr virus antibody in multiple sclerosis patients', a comment letter regarding 'Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients'. European Journal of Neurology. e104-e104.
- (2017). Re: Familieplanlegging, graviditet og amming ved multippel sklerose. Tidsskrift for Den norske legeforening. 259-259.
- (2015). Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'. Acta Neurologica Scandinavica. 368-369.
- (2014). Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments. Annals of clinical and translational neurology. 376-377.
- (2014). Re: Vitamin D-how much is enough, and is more better for your Health? Tidsskrift for Den norske legeforening. 1024-1025.
Doctoral dissertation
- (2010). Environmental risk factors for multiple sclerosis : results from animal and human studies on diet, vitamin D and Epstein-Barr virus.
Academic chapter/article/Conference paper
- (2014). Multippel Sklerose. 10 pages.
Abstract
- (2017). alpha-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients. Multiple Sclerosis. 712-712.
- (2017). Cancer risk in multiple sclerosis. Multiple Sclerosis. 486-487.
- (2013). Antibodies to Epstein-Barr virus and disease activity in multiple sclerosis. Multiple Sclerosis. 400-400.
- (2009). Massive up-regulation of immunoglobulin-related genes in the meninges of multiple sclerosis patients without evidence for Epstein-Barr virus infection. Multiple Sclerosis. S5-S5.
- (2009). Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
- (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
- (2007). Increasing prevalence of multiple sclerosis in the elderly in western Norway. Multiple Sclerosis. S96-S96.
Poster
- (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis.
- (2022). LC-MS/MS quantification of ocrelizumab in the treatment of multiple sclerosis .
- (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis.
- (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies.
Academic literature review
- (2024). Adverse Childhood Experiences and the Risk of Multiple Sclerosis Development: A Review of Potential Mechanisms. International Journal of Molecular Sciences.
- (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. Neurology. E1562-E1573.
- (2020). Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. Journal of Neurology. 15 pages.
- (2019). Neurofilament light chain as a biomarker in multiple sclerosis. Frontiers in Neurology. 1-6.
- (2019). B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 261-271.
- (2019). An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 1187-1199.
- (2015). Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurologica Scandinavica. 29-36.
- (2015). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
- (2013). Neuromyelitis optica. Tidsskrift for Den norske legeforening. 2057-2061.
- (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.
- (2012). Epstein-Barr Virus in Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis—Association and Causation. Viruses. 3701-3730.
Article in business/trade/industry journal
- (2018). Severe multiple sclerosis reactivation after gonadotropin treatment. Multiple Sclerosis and Related Disorders. 38-40.
More information in national current research information system (CRIStin)